Jennifer Heaberlin, DO | Hematology and ...

Dr. Jennifer L. Heaberlin

Claim this profile

AdventHealth Infusion Center Asheville

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
22 reported clinical trials
61 drugs studied

Area of expertise

1

Lung Cancer

Jennifer L. Heaberlin has run 9 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Non-Small Cell Lung Cancer

Jennifer L. Heaberlin has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

AdventHealth Infusion Center Asheville

Image of trial facility.

AdventHealth Infusion Center Haywood

Clinical Trials Jennifer L. Heaberlin is currently running

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

More about Jennifer L. Heaberlin

Clinical Trial Related

9 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Jennifer L. Heaberlin has experience with

  • Pembrolizumab
  • Nivolumab
  • Carboplatin
  • Biospecimen Collection
  • Pemetrexed
  • Ipilimumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jennifer L. Heaberlin specialize in?

Is Jennifer L. Heaberlin currently recruiting for clinical trials?

Are there any treatments that Jennifer L. Heaberlin has studied deeply?

What is the best way to schedule an appointment with Jennifer L. Heaberlin?

What is the office address of Jennifer L. Heaberlin?

Is there any support for travel costs?